Anderson Ribeiro has extensive expertise handling cutting-edge litigation and counseling cases in the Life Sciences & Healthcare sector. In addition, he is expert in product recalls, compliance, and anti-corruption matters, focusing on the needs of the health sciences industry.
He has a distinguished track record in cases involving regulation, government acquisitions, and industrial property before agencies such as the National Health Surveillance Agency (Anvisa), the Ministry of Agriculture (MAPA), and the National Health Agency (ANS), as well as in proceedings before the Federal Audit Court (TCU), the Ministry of Health, the National Institute of Metrology, Quality, and Technology (Inmetro), and state and municipal health departments.
He represents national and multinational companies from the most varied sectors, with a special focus on biotechnology, pharmaceuticals, health products, food, cosmetics, sanitizing products, pesticides, veterinary products, and emerging technologies.
- Specialist in Regulatory Impact Analysis from LUISS (Italy), 2017;
- LL.M in Intellectual Property from Queen Mary (UK), 2013;
- Master of Laws in Competition Law and Regulation from the University of Lisbon (Portugal) – 2012;
- Bachelor of Laws from the State University of Rio de Janeiro (UERJ), 2005.
- Pharma & Medical Device Regulation. Getting the Deal Through, 2020-2021;
- Pharmaceutical IP and competition law in Brazil: overview. Practical Law, 2016-2021;
- Collaboration on Eyeforpharma´s WhitePaper on Access to the Public Health Sector in Brazil (April 2016);
- “The price regulation in Brazil: Roche faces IP rights abuse claims”, Lifesciences Intellectual Property Review, online edition, 2016;
- “The Brazilian Pharmaceutical Sector: A Year in Review”, Life Sciences Intellectual Property Review 2011;
- “Who approves Brazilian Pharma Patents”, World Intellectual Property Review September/October 2010;
- “Impact of the CIS policy on Brazil’s R&D Industry”, Intellectual Property 2010 | Digital Guide;
- “The Misuse of Sham Litigation investigations”, World Intellectual Property Review May/June 2010.
- Member of the Union of Pharmacists of the state of Rio de Janeiro (Sinfar-RJ), and the Union of the Pharmaceutical Products Industry (Sindusfarma);
- Lecturer in the course Access to Medicines and Pharmacoeconomics in the Brazilian Health System at Sindusfarma, 2017 to 2021.
National strategy for the development of the health economic-industrial complex (CEIS) published by the Federal Government
We have advised the first M&A of Pipo Saúde, a digital health and corporate benefits brokerage
We have advised the first M&A of Pipo Saúde, a digital health and corporate benefits brokerage. The company acquired the operation of HRTech Convenia, a benefits brokerage that serves more than 40 clients and covers more than 11,000 lives. The transaction sets Pipo to extend its portfolio to 80,000 lives covered and 220 corporate clients.
Brazilian Telehealth act Comes Into Force
On December 28, 2022, Law No. 14,510/2022 (Telehealth Act), which authorizes the practice of Telehealth throughout the Brazilian territory, came into force. After lengthy discussion and approval by Congress, the President sanctioned the final wording of the Bill of Law 1,998/2020 without vetoes.